TULARIK

Tularik engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company is considered a pioneer in the field of cell signaling and the control of gene expression. The company is focused primarily of three main areas; inflammation, metabolic diseases and oncology. Tularik was founded by David Goeddel along with Steve McKnight and Robert Tjian in 1991. The company was acquired by Amgen for US$ 1.3 billion in 2004.

#SimilarOrganizations #People #Financial #More

TULARIK

Industry:

Biopharma Biotechnology Genetics Health Care Pharmaceutical

Founded:

1991-01-01

Address:

San Francisco, California, United States

Country:

United States

Total Employee:

251+

Status:

Active

Total Funding:

0

Similar Organizations

fedora-pharmaceuticals-logo

Fedora Pharmaceuticals

Fedora Pharmaceuticals engages in the discovery and development of antibiotics for life-threatening microbial drug resistance needs.

novavax-logo

Novavax

Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.

okairos-logo

Okairos

Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.

Current Advisors List

frederick-dotzler_image

Frederick Dotzler Investor @ Tularik
Board_member

Current Employees Featured

steven-mcknight_image

Steven McKnight
Steven McKnight Co-Founder, Director of Research @ Tularik
Co-Founder, Director of Research

yasunori-kaneko_image

Yasunori Kaneko
Yasunori Kaneko Business Executive @ Tularik
Business Executive

Founder

david-goeddel_image

David Goeddel

steven-mcknight_image

Steven McKnight

Stock Details

Company's stock symbol is NASDAQ:TLRK

Investors List

frazier-healthcare-ventures_image

Frazier Healthcare Partners

Frazier Healthcare Partners investment in Funding Round - Tularik

More informations about "Tularik" on Search Engine